• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alpha Cognition Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8/22/25 5:26:53 PM ET
    $ACOG
    Get the next $ACOG alert in real time by email
    false 0001655923 A1 00-0000000 0001655923 2025-08-22 2025-08-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 22, 2025

     

    Alpha Cognition Inc.

    (Exact name of registrant as specified in its charter)

     

    British Columbia   001-42403   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification Number)

     

    1452 Hughes Rd., Ste 200
    Grapevine, Texas
      76051
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: 604-564-9244

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbol   Name of each exchange on which registered:
    Common Shares, no par value   ACOG   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

      

     

     

     

     

    Item 1.01Entry into a Material Definitive Agreement

     

    On August 22, 2025, Alpha Cognition Inc. (the “Company”) entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) as sales agent. Under the terms of the ATM Agreement, the Company will be entitled to sell, at its sole discretion and from time to time as it may choose, common shares in the capital of the Company (“Shares”) through Wainwright, with such sales having an aggregate gross sales value of up to US$75.0 million (the “Offering”). The ATM Agreement will remain in full force and effect until the date that the ATM Agreement is terminated in accordance with the terms therein.

     

    Subject to the terms and conditions of the Agreement, Wainwright will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. The Company has provided Wainwright with customary indemnification rights, and Wainwright will be entitled to a commission at a commission rate of up to 3.0% of the gross sales price of the Shares sold.

     

    Sales of the Shares, if any, under the Agreement may be made in transactions that are deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made by means of ordinary brokers’ transactions, including on the Nasdaq Capital Market, at market prices or as otherwise agreed with Wainwright. The Company has no obligation to sell any of the Shares, and may at any time suspend offers under the Agreement or terminate the Agreement.

     

    This report shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

     

    The ATM Agreement was filed as an exhibit to the Company’s shelf registration statement on Form S-3 (File No. 333-289792) previously filed with the Securities and Exchange Commission on August 22, 2025 (the “Registration Statement”). The description of the material terms of the ATM Agreement above is qualified in its entirety by reference to the ATM Agreement filed as Exhibit 1.2 to the Registration Statement.

     

    The opinion of the Company’s counsel regarding the validity of the Shares to be issued pursuant to the ATM Agreement and filed with the Registration Statement as Exhibit 5.3.

     

     

    Item 9.01Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    1.2   At the Market Offering Agreement, dated August 22, 2025, by and between the Company and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.2 to the Company’s Registration Statement on Form S-3 as filed with  the Commission on August 22, 2025 (File No. 333-289792)
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ALPHA COGNITION INC.
       
      By: /s/ Michael McFadden
        Michael McFadden
        Chief Executive Officer
    Dated: August 22, 2025  

     

     

    Get the next $ACOG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOG

    DatePrice TargetRatingAnalyst
    3/18/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wills Robert James bought $127,328 worth of shares (15,000 units at $8.49) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    8/21/25 12:36:53 PM ET
    $ACOG

    Director Mertz Phillip Joseph sold $250,002 worth of shares (27,778 units at $9.00), decreasing direct ownership by 55% to 22,462 units (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    8/20/25 4:26:14 PM ET
    $ACOG

    Director Mertz Leonard Powell bought $250,002 worth of shares (27,778 units at $9.00) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    8/20/25 4:06:08 PM ET
    $ACOG

    $ACOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

    Key Highlights ZUNVEYL Launch Momentum: Completed the second quarter of commercialization, generating approximately $2.8 million in total revenue for the quarter. Significant Growth: 102% quarterly increase in pharmacy orders, with record prescription volumes achieved each month during the quarter. Expanding Prescriber Base: Q3 prescribers surpassed 500, representing 55% growth over the prior quarter. Disciplined Expense Management: Full-year operating spend guidance reduced to $28–30 million; the Company expects operating profitability in 2027. Strong Balance Sheet: $35.4 million in cash and cash equivalents as of September 30, 2025, excluding the October capital raise, whic

    11/13/25 4:00:00 PM ET
    $ACOG

    Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025

    Management to host conference call on Thursday, November 13, 2025 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its third quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, m

    10/30/25 8:30:00 AM ET
    $ACOG

    Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL® (Benzgalantamine) at two upcoming scientific meetings: the American Society of Consultant Pharmacists (ASCP) Annual Meeting (October 23–25, 2025) and the Neuroscience Education Institute (NEI) Annual Congress (November 6–9, 2025).The Company's accepted poster presentations include: ASCP Annual Meeting Poster 12: Acetylcholinesterase Inhibitors and Psychotropic Medication Use in Alzheimer's Disease and Related Dem

    10/14/25 4:30:00 PM ET
    $ACOG

    $ACOG
    SEC Filings

    View All

    SEC Form 10-Q filed by Alpha Cognition Inc.

    10-Q - Alpha Cognition Inc. (0001655923) (Filer)

    11/13/25 4:43:08 PM ET
    $ACOG

    Amendment: Alpha Cognition Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K/A - Alpha Cognition Inc. (0001655923) (Filer)

    10/14/25 5:45:53 PM ET
    $ACOG

    Alpha Cognition Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Alpha Cognition Inc. (0001655923) (Filer)

    10/14/25 4:10:35 PM ET
    $ACOG

    $ACOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Alpha Cognition with a new price target

    H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00

    3/18/25 7:48:36 AM ET
    $ACOG

    $ACOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wills Robert James bought $127,328 worth of shares (15,000 units at $8.49) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    8/21/25 12:36:53 PM ET
    $ACOG

    Director Mertz Leonard Powell bought $250,002 worth of shares (27,778 units at $9.00) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    8/20/25 4:06:08 PM ET
    $ACOG

    $ACOG
    Leadership Updates

    Live Leadership Updates

    View All

    Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

    4/10/25 8:30:00 AM ET
    $ACOG
    $CBAY
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic

    1/14/25 8:30:00 AM ET
    $ACOG

    $ACOG
    Financials

    Live finance-specific insights

    View All

    Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

    Key Highlights ZUNVEYL Launch Momentum: Completed the second quarter of commercialization, generating approximately $2.8 million in total revenue for the quarter. Significant Growth: 102% quarterly increase in pharmacy orders, with record prescription volumes achieved each month during the quarter. Expanding Prescriber Base: Q3 prescribers surpassed 500, representing 55% growth over the prior quarter. Disciplined Expense Management: Full-year operating spend guidance reduced to $28–30 million; the Company expects operating profitability in 2027. Strong Balance Sheet: $35.4 million in cash and cash equivalents as of September 30, 2025, excluding the October capital raise, whic

    11/13/25 4:00:00 PM ET
    $ACOG

    Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025

    Management to host conference call on Thursday, November 13, 2025 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its third quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, m

    10/30/25 8:30:00 AM ET
    $ACOG

    Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update

    Key Highlights ZUNVEYL Launch Momentum: Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Advancing ALPHA-1062: Completed pre-clinical Bomb Blast study in collaboration with the U.S. Department of Defense and the Seattle Institute of Biomedical and Clinical Research. Strong Balance Sheet: Cash and cash equivalents of $39.4 million as of June 30, 2025, supporting an estimated cash runway of approximately two years at the current utilization rate. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company") today announced its financial results for the second quarter ended June 30, 2025.

    8/14/25 8:30:00 AM ET
    $ACOG